Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting HNF4α

ABSTRACT: The emergence of drug-resistant viruses against nucleot(s)ide analogs (NAs), which are the main treatment for chronic hepatitis B virus (HBV) infection, has become a problem. To discover novel anti-HBV compounds with a low risk of emergence of drug-resistant viruses, we performed screening of a G protein-coupled receptor-associated compound library and identified Rimonabant as a candidate. Transcriptome analysis of Rimonabant-treated primary hepatocytes by RNA sequencing revealed that the transcriptional activity of HNF4α, which is known to stimulate viral RNA synthesis, was depressed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139597 | GEO | 2020/01/26

REPOSITORIES: GEO